ResMed Inc. (RMD)
Healthcare · end-of-day data as of Oct 16, 2026
The average 12-month analyst price target for RMD is $247.91, 3.7% above the last close of $238.97 on Oct 16, 2026; targets range from $210.15 to $298.88. Rating consensus: Buy.
Snapshot
- P/E23.0x
- P/E vs sector-18.4%
- P/E vs own-0.4%
- Target upside+3.7%
- ConsensusBuy
- Market cap$33.61B
- FCF yield+8.6%
- Insiders-$5.29M
- Earnings in13d
- News0.00
Why it moved
ResMed Inc. (RMD) fell 1.3% on Oct 16, 2026.
The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move came from the market as a whole.
0 stories on the day (30-day average 0.2).
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $238.97 · -10.6% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendbullish
- Sector▲ +16.0%
- MAs20▲ 50▲ 100▲ 200▲
- Above MAs4 of 4 above
- MA20×50Death 10d ago
- RSI67
- Support-4.0%
- Resistance+1.2%
- Off 52w high-12.7%
- Off ATH-17.8%
- 52w range$238.97
- Bollingerupper half
- MACD1.90
- ATR+2.2%
- Volume2.4x
Analyst price targets
12 firms with a target in the last 12 months · last close $238.97 · as of Oct 16, 2026
Strong buy 2 · Buy 7 · Hold 10 · Sell 1 · Strong sell 0
Revenue and free cash flow
Q4 FY2026: Revenue +8.6% year over year, free cash flow 112.7% of revenue, operating margin 30.7%.
| Q4 FY2026 | Jun 30, 2026 | $1.46B | 2.64 | $1.65B | 58.8% | 30.7% | 26.2% |
| Q3 FY2026 | Mar 31, 2026 | $1.43B | 2.71 | $520M | 62.2% | 34.9% | 27.9% |
| Q2 FY2026 | Dec 31, 2025 | $1.42B | 2.68 | $305M | 62.2% | 35.0% | 27.6% |
| Q1 FY2026 | Sep 30, 2025 | $1.34B | 2.37 | $414M | 61.5% | 33.4% | 26.1% |
| Q4 FY2025 | Jun 30, 2025 | $1.35B | 2.58 | $508M | 60.8% | 33.7% | 28.2% |
| Q3 FY2025 | Mar 31, 2025 | $1.29B | 2.48 | $555M | 59.3% | 33.0% | 28.3% |
| Q2 FY2025 | Dec 31, 2024 | $1.28B | 2.34 | $290M | 58.6% | 32.5% | 26.9% |
| Q1 FY2025 | Sep 30, 2024 | $1.22B | 2.11 | $306M | 58.6% | 31.6% | 25.4% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $426.70 | -0.3% | -28.0% | +12.1% | 48.5 | $151B | |
| 2 |  | $191.75 | -1.0% | -1.0% | -6.2% | 57.8 | $52.23B | |
| 3 |  | $69.16 | -1.9% | -1.9% | -0.5% | — | $34.16B | |
| 4 | | $238.97 | -1.3% | -12.7% | +3.7% | 23.0 | $33.61B | |
| 5 |  | $384.02 | +0.3% | 0.0% | +1.9% | 49.1 | $27.03B | |
| 6 |  | $85.81 | -2.3% | -7.2% | +3.6% | 10.5 | $14.61B | |
| 7 |  | $25.28 | -1.9% | -10.8% | -14.8% | — | $13.07B | |
| 8 |  | $57.94 | +0.9% | -31.3% | +0.9% | 19.8 | $11.02B |
Data as of Oct 16, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.